Are the newer antidiabetic agents worth the cost?

Sudhakar Pemminati; Richard Mark Millis; Ashwin Kamath; Ashok Kudgi Shenoy; Shivapraksh Gangachannaiah

doi:10.7860/JCDR/2016/17683.7384

Are the newer antidiabetic agents worth the cost?

Sudhakar Pemminati^*
, Richard Mark Millis
, Ashwin Kamath
, Ashok Kudgi Shenoy
, Shivapraksh Gangachannaiah

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	FL01
Journal	Journal of Clinical and Diagnostic Research
Volume	10
Issue number	3
DOIs	https://doi.org/10.7860/JCDR/2016/17683.7384
Publication status	Published - 01-03-2016

All Science Journal Classification (ASJC) codes

Clinical Biochemistry

Access to Document

10.7860/JCDR/2016/17683.7384

Cite this

@article{e69c4b94e0f5446d81eb875cf1d8130e,

title = "Are the newer antidiabetic agents worth the cost?",

author = "Sudhakar Pemminati and Millis, \{Richard Mark\} and Ashwin Kamath and Shenoy, \{Ashok Kudgi\} and Shivapraksh Gangachannaiah",

year = "2016",

month = mar,

day = "1",

doi = "10.7860/JCDR/2016/17683.7384",

language = "English",

volume = "10",

pages = "FL01",

journal = "Journal of Clinical and Diagnostic Research",

issn = "2249-782X",